Dr. Reddy seeks nod for DCGI approval for Phase 3 clinical trials of Sputnik V in India

Dr Reddy’s Laboratories has applied permission to the Drugs Controller General of India (DCGI) for conducting the phase-3 human clinical trials of Sputnik V, Russian coronavirus vaccine against COVID-19 in India, according to the sources.

“Dr Reddy’s Laboratories has applied to the DCGI seeking permission to conduct phase-3 human clinical trials of the Sputnik V vaccine against COVID-19 developed by Russia. The DCGI will carry out a technical evaluation of the application before giving its approval,” according to the sources.

Dr. Reddy has partnered with Russian Direct Investment Fund (RDIF) to conduct clinical trials of Sputnik V as well as its distribution.
Upon regulatory approval in India, RDIF will supply to Dr Reddy’s 100 million doses of the vaccine, the firm said last month.

Related Posts

  • Pharma
  • June 19, 2025
  • 101 views
Pharma stock jumps after receiving approval from UK’s MHRA to sell new pharma product

This small-cap pharma stock, engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations across global markets, rose over 2% in today’s trade after receiving approval for its product…

  • Pharma
  • June 19, 2025
  • 128 views
HIV prevention drug hailed as a ‘breakthrough’ gets FDA approval

A drug with the potential to drastically curb the HIV epidemic just cleared its first regulatory hurdle. On Wednesday, the Food and Drug Administration approved lenacapavir for the prevention of…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Pharma stock jumps after receiving approval from UK’s MHRA to sell new pharma product

Pharma stock jumps after receiving approval from UK’s MHRA to sell new pharma product

HIV prevention drug hailed as a ‘breakthrough’ gets FDA approval

HIV prevention drug hailed as a ‘breakthrough’ gets FDA approval

ED raids three pharma units in Baddi, Nalagarh

ED raids three pharma units in Baddi, Nalagarh

Glenmark Pharma: FDA concludes inspection at US facility, issues five observations

Glenmark Pharma: FDA concludes inspection at US facility, issues five observations